ArriVent BioPharma, Inc. (AVBP)

Price$28.90Cached quoteAs of 2026-09-19 15:50 UTC

AI: Fair-priced

Price checkThe valuation looks balanced because strong funding meets an unproven, concentrated drug pipeline.

Using 49.3 million shares reported on August 10, the equity is valued near $1.43 billion. Subtracting $373.1 million of cash and investments and adding negligible debt leaves roughly $1.06 billion assigned to the pipeline. With no revenue or approved product, earnings multiples are not useful. That pipeline value is substantial but not clearly excessive before pivotal firmonertinib data, making the observed price a balanced trade between a credible late-stage drug and the all-or-nothing risks of trials, approval, patents, and launch.

Big pictureLosses remain large, and trial results matter far more than ordinary economic cycles.

ArriVent has no product revenue. It lost $166.3 million and used $160.6 million in operations during 2025; the first half of 2026 added a $93.2 million loss and $81.5 million of operating cash use. At that recent pace, $373.1 million of cash and investments equals about 2.3 years of funding, broadly supporting management’s runway into 2028. Drug-development spending is not strongly tied to economic cycles, but results are volatile because trial milestones, license payments, and hiring can make quarterly costs jump.

Business strengthThe balance sheet buys time, but repeated share sales reduce each owner’s claim.

At June 30, current assets were $394.2 million against $27.8 million of current liabilities, while debt was only $0.4 million. That cushion protects near-term development, but it was purchased partly with dilution: ArriVent sold 5.36 million shares for $140.0 million net in 2026’s first half. Shares rose from 33.7 million at year-end 2024 to 49.3 million by August 10, about 46%. A further $229.1 million remained under its share-sale program, so future funding can again reduce each existing share’s ownership.

What could change the storyPositive pivotal results could justify today’s hopes; failure or weaker patent protection would not.

The strongest bull case is a positive FURVENT Phase 3 result, due in 2026’s second half, followed by approval and meaningful firmonertinib sales outside Greater China. Earlier FURTHER data showed a 68.2% confirmed response rate and 16.0-month median time without disease worsening in 22 first-line patients, encouraging but too small to settle value. The bear case is failed pivotal data or narrower patent protection. Even success carries up to $765 million of contingent milestones plus high-single-digit to low-mid-teen sales royalties. Today’s pipeline value therefore requires meaningful success odds, not merely continued testing.

AI: News

Pivotal readout approachesThe lead drug’s decisive trial result remains close, but its expected window moved later.

On August 12, ArriVent said top-line results from the global FURVENT Phase 3 study of first-line firmonertinib for a rare lung-cancer mutation were expected in the second half of 2026. In March, management had said mid-2026, so the window moved later. Enrollment is complete, and the result is the clearest near-term test of whether firmonertinib can support approval. Any stock reaction around the update cannot be confidently separated from broader trading.

Share sales extend runwayShare sales lowered near-term funding risk while increasing claims on future drug value.

Results filed August 12 showed that ArriVent sold 5,358,318 shares during the first half for $140.0 million net. Cash and investments reached $373.1 million, which management expects to fund operations into 2028, versus guidance to the third quarter of 2027 at year-end. The financing lowers near-term funding risk, but the extra shares spread future drug value across more owners; roughly $229.1 million of additional share-sale capacity remained.

Firmonertinib patent reviewA review of one firmonertinib patent creates uncertainty around the lead drug’s protection.

On July 22, the United States Patent and Trademark Office granted an anonymous third party’s request to reexamine one patent covering firmonertinib. The review can confirm, narrow, or cancel claims; ArriVent says the challenge lacks merit. Other United States patents and applications for the drug are not in this proceeding. The economic effect is therefore uncertain, but weaker protection could shorten exclusivity for the company’s lead asset or raise defense costs.

China license for ARR-002The ARR-002 China deal may share development work and add payments without surrendering wider rights.

On August 11, ArriVent licensed ARR-002 rights in Greater China to Allist while keeping rights elsewhere. The agreement may deliver up to $80.6 million through an upfront payment and later milestones, plus mid-single-digit to low-double-digit royalties on regional sales. ArriVent will supply the initial joint global study. This could share development work and create regional income, but the upfront amount was not disclosed and most value depends on successful development and sales.

Loading local price history

Revenue

2022

2023

2024

2025

Net income

2022

2023

2024

2025

Free cash flow

No reported data

Total cash / debt

CashTotal debt

2022

2023

2024

2025

Financial statements

	2025	2024	2023	2022
Revenue	$0	$0	$0	$0
Research & development	$153.4M	$79.0M	$64.9M	$30.4M
Operating expenses	$177.5M	$94.3M	$74.6M	$36.9M
Operating income	−$177.5M	−$94.3M	−$74.6M	−$36.9M
EBITDA	−$177.5M	−$94.3M	−$74.6M	−$36.9M
Net income	−$166.3M	−$80.5M	−$69.3M	−$36.9M
Basic EPSper basic share	-$4.32	-$2.56	-$32.38	-$1.15
Diluted EPSper diluted share	-$4.32	-$2.56	-$32.38	-$1.15

Review official source filings ↗

Owners

Reported shareholders

Reference date Jun 30, 2026

9.35%of listed shares

MONTANOVA CAPITAL, LLC4.52M shares · Jun 30, 2026

View holders

Top 20 reported holders of AVBP
Holder	% owned
MONTANOVA CAPITAL, LLC	9.35%4.52M shares
INFINITUM ASSET MANAGEMENT, LLC	9.19%4.44M shares
HHLR ADVISORS, LTD.	8.13%3.93M shares
BlackRock, Inc.	6.73%3.25M shares
ORBIMED ADVISORS LLC	6.27%3.03M shares
FMR LLC	5.75%2.78M shares
Octagon Capital Advisors LP	4.08%1.97M shares
VANGUARD CAPITAL MANAGEMENT LLC	3.67%1.77M shares
Sofinnova Investments, Inc.	3.51%1.7M shares
STATE STREET CORP	3.50%1.69M shares
Vivo Capital, LLC	3.48%1.68M shares
NOVO HOLDINGS A/S	3.10%1.5M shares
General Catalyst Group Management, LLC	3.09%1.49M shares
Logos Global Management LP	2.07%1M shares
GEODE CAPITAL MANAGEMENT, LLC	2.01%972.63K shares
D. E. Shaw & Co., Inc.	1.80%872.01K shares
GOLDMAN SACHS GROUP INC	1.77%853.72K shares
HSG Holding Ltd	1.37%663.31K shares
Point72 Asset Management, L.P.	1.17%566.8K shares
LaChapelle Robin	≈1.10%530.21K shares

Percentages use 48.32M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.

Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.

Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data

Insider buys & sells

Jul 1, 2024–Jun 30, 2026

Buys0$0.00 disclosed value

Sells (SEC code S)1$12.98M disclosed value

Transaction	Insider	Type	Shares	Price	Value	Owned after
Dec 10, 2025Form 4	HHLR ADVISORS, LTD. +1TenPercentOwner	SellCommon Stock · indirect	555.6K	$23.37	$12.98M	3.93M

Review ownership filings at SEC.gov ↗

Community posts

View community

It’s quiet here.

No posts about AVBP yet. Start the conversation.

Write the first post

ArriVent BioPharma, Inc. (AVBP)

Financial charts

Financial statements

Owners

Insider buys & sells

Community posts

It’s quiet here.